BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21 Suppl 2:e25058. [PMID: 29633561 DOI: 10.1002/jia2.25058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Chhatwal J, Chen Q, Wang X, Ayer T, Zhuo Y, Janjua NZ, Kanwal F. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. JAMA Netw Open 2019;2:e193613. [PMID: 31074817 DOI: 10.1001/jamanetworkopen.2019.3613] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
2 Lazarus JV, Pericàs JM, Colombo M, Ninburg M, Wiktor S, Thursz M. Viral hepatitis: "E" is for equitable elimination. J Hepatol 2018;69:762-4. [PMID: 30049544 DOI: 10.1016/j.jhep.2018.06.018] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
3 Uusküla A, Talu A, Rannap J, Barnes DM, Jarlais DD. Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia. Harm Reduct J 2021;18:39. [PMID: 33794927 DOI: 10.1186/s12954-021-00485-5] [Reference Citation Analysis]
4 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Sukthong P, Poovorawan K, Tangkijvanich P, Poovorawan Y. Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy. PLoS One 2018;13:e0202991. [PMID: 30138441 DOI: 10.1371/journal.pone.0202991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Iglesias M, Mc Hugh T, Crowley D, Naughton AM, Horan A, Ianache I, Lazar S, Popa I, Menezes D, Lambert JS. HepCare Europe-A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA. Int J Infect Dis 2020;91:246-51. [PMID: 31785401 DOI: 10.1016/j.ijid.2019.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Jülicher P, Chulanov VP, Pimenov NN, Chirkova E, Yankina A, Galli C. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis. PLoS One 2019;14:e0219687. [PMID: 31310636 DOI: 10.1371/journal.pone.0219687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis 2020;222:S758-72. [PMID: 33245354 DOI: 10.1093/infdis/jiaa366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21 Suppl 2:e25058. [PMID: 29633561 DOI: 10.1002/jia2.25058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
9 Li T, Wang R, Zhao Y, Su S, Zeng H. Public awareness and influencing factors regarding hepatitis B and hepatitis C in Chongqing municipality and Chengdu City, China: a cross-sectional study with community residents. BMJ Open 2021;11:e045630. [PMID: 34341038 DOI: 10.1136/bmjopen-2020-045630] [Reference Citation Analysis]
10 Shokr A, Pacheco LGC, Thirumalaraju P, Kanakasabapathy MK, Gandhi J, Kartik D, Silva FSR, Erdogmus E, Kandula H, Luo S, Yu XG, Chung RT, Li JZ, Kuritzkes DR, Shafiee H. Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano 2021;15:665-73. [PMID: 33226787 DOI: 10.1021/acsnano.0c06807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Barror S, Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Crowley D, Horan A, Naughton AM, Iglesias M, Ianache I, Lazar S, Popa I, McHugh T, Menezes D, Tinago W, Lambert JS. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother 2019;74:v39-46. [PMID: 31782499 DOI: 10.1093/jac/dkz455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Pyziak-Kowalska KA, Horban A, Bielecki M, Kowalska J. Missed opportunities for diagnosing viral hepatitis C in Poland. Results from routine HCV testing at the Emergency Department in the Hospital for Infectious Diseases in Warsaw. Clin Exp Hepatol 2019;5:294-300. [PMID: 31893241 DOI: 10.5114/ceh.2019.89148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Reference Citation Analysis]
16 Prabdial-Sing N, Gaelejwe L, Makhathini L, Thaver J, Manamela MJ, Malfeld S, Spearman CW, Sonderup M, Scheibe A, Young K, Hausler H, Puren AJ. The performance of hepatitis C virus (HCV) antibody point-of-care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa. Health Sci Rep 2021;4:e229. [PMID: 33614978 DOI: 10.1002/hsr2.229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kabamba AT, Mwamba CM, Dessilly G, Dufrasne F, Kabamba BM, Longanga AO. Evaluation of the analytical performance of six rapid diagnostic tests for the detection of viral hepatitis B and C in Lubumbashi, Democratic Republic of Congo. J Virol Methods 2020;285:113961. [PMID: 32860797 DOI: 10.1016/j.jviromet.2020.113961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Mohamed Z, Al-Kurdi D, Nelson M, Shimakawa Y, Selvapatt N, Lacey J, Thursz MR, Lemoine M, Brown AS. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. Int J Drug Policy 2020;75:102608. [PMID: 31759307 DOI: 10.1016/j.drugpo.2019.102608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
19 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
20 Lacombe K, Klein MB. The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low- to high-income settings. J Int AIDS Soc 2018;21 Suppl 2:e25073. [PMID: 29633554 DOI: 10.1002/jia2.25073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
22 AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
23 Narayanamurthy V, Jeroish ZE, Bhuvaneshwari KS, Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Anal Methods 2021;13:740-63. [PMID: 33511975 DOI: 10.1039/d0ay02045a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Harrington PR, Komatsu TE, Sun H, Naeger LK. Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays. Clin Infect Dis 2020;70:327-30. [PMID: 31075159 DOI: 10.1093/cid/ciz385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mohamed Z, Mbwambo J, Rwegasha J, Mgina N, Doulla B, Mwakale P, Tuaillon E, Chevaliez S, Shimakawa Y, Taylor-Robinson SD, Thursz MR, Brown AS, Lemoine M. In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania. Liver Int 2020;40:514-21. [PMID: 31778282 DOI: 10.1111/liv.14315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
26 Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, Ouzan D, Papatheodoridis G, Ramji A, Borgia SM, Wedemeyer H, Losappio R, Pérez-Hernandez F, Wick N, Brown RS Jr, Lampertico P, Doucette K, Ntalla I, Ramroth H, Mertens M, Vanstraelen K, Turnes J. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int 2020;40:1841-52. [PMID: 32449966 DOI: 10.1111/liv.14537] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
27 Li J, Li Y, Zhai X, Cao Y, Zhao J, Tang Y, Han K. Sensitive electrochemical detection of hepatitis C virus subtype based on nucleotides assisted magnetic reduced graphene oxide-copper nano-composite. Electrochemistry Communications 2020;110:106601. [DOI: 10.1016/j.elecom.2019.106601] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
28 Ding YJ, Lu CK, Chen WM, Tung SY, Wei KL, Shen CH, Hsieh YY, Yen CW, Chang KC, Chiu WN, Hung CH, Lu SN, Chang TS. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis. J Gastroenterol Hepatol 2021. [PMID: 33978973 DOI: 10.1111/jgh.15546] [Reference Citation Analysis]
29 Catlett B, Lamoury FMJ, Bajis S, Hajarizadeh B, Martinez D, Mowat Y, Cunningham PH, Jacka BP, Cloherty GA, Marks P, Dore GJ, Grebely J, Applegate TL. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. J Viral Hepat 2019;26:1423-30. [PMID: 31448470 DOI: 10.1111/jvh.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Li T, Su S, Zhao Y, Deng R, Fan M, Wang R, Sharma M, Zeng H. Barriers to the Prevention and Control of Hepatitis B and Hepatitis C in the Community of Southwestern China: A Qualitative Research. Int J Environ Res Public Health 2019;16:E231. [PMID: 30650581 DOI: 10.3390/ijerph16020231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
31 Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. Aliment Pharmacol Ther 2019;49:1126-33. [PMID: 30843268 DOI: 10.1111/apt.15201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
32 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]